mClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, the Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, and ...

Stockholders have approved Kenvue's merger with Kimberly-Clark. The resulting merger is between two Dividend Kings. Kenvue just reported a strong first quarter. 10 stocks we like better than Kenvue › ...

Richard Evan Caesar, M.D. #MD20302 (Date of Action 07/12/2022) On July 12, 2022, the Board considered the request for termination of the Surgical Proctor requirement contained in the November 9, 2021 ...

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600–Mutant Solid Tumors ASCO Guidelines provide ...

Represents costs recorded to Other operating expense, net, incurred in connection with the separation of our former Biosciences and Diagnostic Solutions business and the combination of the business ...

The Pyxis Pro Dispensing Solution for medication. [Image courtesy of BD] BD (NYSE:BDX) announced that it entered into a strategic partnership with Wellstar Health System to enhance medication delivery ...

The companies said the collaboration “reflects a shared vision to strengthen safety, efficiency, and patient outcomes across the continuum of care." (luckystep/iStock/Getty Images Plus) Marietta, ...

Amid rising tensions in West Asia and concerns over LPG supply, India is ramping up fuel imports. The tanker Pyxis Pioneer has arrived at New Mangalore Port with over 16,000 tonnes of LPG from the US.

BD and Sinteco aim to provide an automated solution that takes bulk medication shipments and sorts them into individually bar-coded doses. (Sinteco) BD has inked a technological partnership with ...

Hello, and welcome to BD's First Fiscal Quarter 2026 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at ...

Adjusted EPS of $2.91 beat forecasts by 3.56%. Revenue reached $5.3 billion, surpassing expectations by 2.91%. Stock fell 2.49% in pre-market trading despite earnings beat. Operational margins ...

Earnings call BDX delivered Q1 FY2026 revenue of $5.3B (+0.4% YoY) and adjusted EPS of $2.91 (down 15.2% YoY), both ahead of expectations. New BD grew 2.5%, driven by strength in Biologics, PureWick, ...